Trial Profile

Efficacy of filgrastim to prevent neutropenia in patients with lung cancer treated with cyclophosphamide, doxorubicin and etoposide chemotherapy regimens.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Filgrastim (Primary)
Indications Neutropenia
Focus Therapeutic Use
Sponsors Amgen

Most Recent Events

10 Jun 2014 New trial record
03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
30 May 2014 Primary endpoint 'Infection-rate' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com